Imagen de Portada
Código QR

The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus.

Background: No previous study, to the best of our knowledge, has examined both the time trend and impact of not having insurance or prescription medication cost coverage (PMCC) on the usage of type 2 diabetes and hypertension oral medications in Ontario and New Brunswick, Canada. Methods: We used da...

Descripción completa

Publicado en:Healthcare Policy Vol. 16; no. 2; pp. 82 - 101
Autores principales: AMOUD, RAZAN, GRINDROD, KELLY, COOKE, MARTIN, ALSABBAGH, MHD WASEM
Formato: research tables/charts Journal Article
Publicado: Longwoods Publishing Nov2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147481158&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 147481158
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17156572
        902I
      jtl: Healthcare Policy
      issn: 17156572
      maglogo: N
    pubinfo:
      dt: Nov2020
      vid: 16
      iid: 2
      pid: 20495
      pub: Longwoods Publishing
      place: Toronto, Ontario
    artinfo:
      ui:
        147481158
        147481158
        147481158
        10.12927/hcpol.2020.26351
        147481158
      ppf: 82
      ppct: 19
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus.
      aug:
        au:
          AMOUD, RAZAN
          GRINDROD, KELLY
          COOKE, MARTIN
          ALSABBAGH, MHD WASEM
        affil: School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON
      sug:
        subj:
          Drugs, Prescription Economics
          Health Care Costs Canada
          Hypertension Drug Therapy
          Diabetes Mellitus, Type 2 Drug Therapy
          Administration, Oral
          Insurance Coverage
          Human
          Cross Sectional Studies
          Surveys
          Canada
          Adolescence
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Male
          Female
          Socioeconomic Factors
          Disease Duration
          Chi Square Test
          Multiple Logistic Regression
          Confidence Intervals
          Regression
          Logistic Regression
          Data Analysis Software
          Descriptive Statistics
          Odds Ratio
          Health Care Costs Statistics and Numerical Data
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab:
        Background: No previous study, to the best of our knowledge, has examined both the time trend and impact of not having insurance or prescription medication cost coverage (PMCC) on the usage of type 2 diabetes and hypertension oral medications in Ontario and New Brunswick, Canada. Methods: We used data from the Canadian Community Health Survey (CCHS) from 2007 to 2014 to examine the time trend and impact of PMCC. A multivariable-adjusted logistic regression model was fitted. Results: The pseudo-cohort included 23,215 individuals representing a population of approximately 8.7 million people. Overall, 20.0% of respondents reported absence of PMCC. This proportion increased slightly from 19.6% (95% confidence interval [CI] 95% CI [17.5, 22.5]) to 20.7% (95% CI [16.9, 23.1]). Adjusted odds ratios (OR) showed that uninsured individuals were 23% less likely to use their medications (OR = 0.77, 95% CI [0.657, 0.911]). Conclusion: There was a slight decline in PMCC over time and this decline was associated with reduced use of medications for type 2 diabetes and hypertension.
        Contexte : Aucune étude, à notre connaissance, n'a examiné à la fois la tendance temporelle et l'impact de l'absence de régime d'assurance ou de couverture du coût des médicaments d'ordonnance (CCMO) sur l'utilisation des médicaments oraux contre le diabète de type 2 et l'hypertension en Ontario et au Nouveau-Brunswick, au Canada. Méthode : Nous avons utilisé les données de l'Enquête sur la santé dans les collectivités canadiennes (ESCC) de 2007 à 2014 pour examiner la tendance temporelle et l'impact de la CCMO. Un modèle de régression logistique ajusté à plusieurs variables a été employé. Résultats : La pseudo-cohorte comprenait 23 215 individus représentant une population d'environ 8,7 millions de personnes. Dans l'ensemble, 20,0 % des répondants ont signalé ne pas avoir de CCMO. Cette proportion a légèrement augmenté, passant de 19,6 % (intervalle de confiance [IC] à 95% [17,5; 22,5]) à 20,7 % (IC à 95% [16,9; 23,1]). Les rapports de cote (RC) corrigés montrent que les personnes non assurées sont moins susceptibles, dans une proportion de 23 %, d'utiliser leurs médicaments (RC = 0,77, IC à 95% [0,657; 0,911]). Conclusion : Il y a eu une légère baisse de la CCMO au fil du temps et cette baisse est associée à une réduction de l'utilisation des médicaments pour le diabète de type 2 et l'hypertension.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N